Learn the health rankings in your state, based on 33 measures.
“For nearly 3 decades,America’s Health Rankingshas provided an analysis of national health on a state-by-state basis by evaluating a historical and comprehensive set of health, environmental, and socioeconomic data to determine national health benchmarks and state rankings.”
“America’s Health Rankings® is built upon the World Health Organization definition of health: ‘Health is a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.’ Our model reflects that determinants of health directly influence health outcomes. Individual measures are divided into five categories; a health outcomes category and four categories of health determinants: behaviors, community & environment, policy, and clinical care.”
The health rankings are based on 33 different measures. And the research includes all 50 states. The measures relate to behavior, community and environment, policy, and clinical care, as well as health-related outcomes.
Click the image to see the results for your state. Choose the “Overall in 2018” tab. Then, click on the state to see more in-depth information. And choose the middle of three tabs.
“Our panel of immunotherapy experts discusses the latest cancer immunotherapy advances featured at the world’s largest oncology conference—the 2018 annual meeting of the American Society of Clinical Oncology (ASCO)—with topics including combination immunotherapy, biomarker development, CAR T cell therapies, and new approaches to immune-based cancer treatment.”
“Panelists include Charles G. Drake, M.D., Ph.D., of New York-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O’Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates.”
“We present this video as part of the Answer to Cancer patient and caregiver education program of the Cancer Research Institute, and feature it as part of our sixth annual global awareness campaign, Cancer Immunotherapy Month, in June.”
“Apple and Stanford Medicine enrolled more than 400,000 participants in the Apple Heart Study since its launch in November of 2017 — making it the largest study on atrial fibrillation (AFib) ever conducted. The study will help Apple explore how its Watch can be used to identify AFib, a common type of irregular heartbeat that heightens the risk of stroke and cardiovascular disease.”
“AFib costs the U.S. around $6 billion annually, and is responsible for about 130,000 deaths and 750,000 hospitalizations in the US every year, the CDC reports. And AFib detection has been one of Apple’s strategic focuses in healthcare thus far — the tech giant released the Watch Series 4 with an FDA-cleared AFib detection feature in September, for example.”
“The Apple Heart Study app uses data from Apple Watch to identify irregular heart rhythms, including those from potentially serious heart conditions such as atrial fibrillation. Apple is conducting this research study in collaboration with Stanford Medicine to improve the technology used to detect and analyze irregular heart rhythms, like atrial fibrillation – a leading cause of stroke.”
“Amazon is now offering an exclusive brand of consumer-focused medical devices to help consumers manage diabetes and hypertension, according to CNBC. The brand, dubbed Choice, was developed by health consultancy firm Arcadia Group. Choice will initially include blood pressure cuffs and glucose monitors with supporting mobile apps that offer measurement tracking and reminders. Exclusive consumer-facing medical supplies will complement Amazon’s existing offerings and should be a boon for its healthcare play.”
“But Amazon will need to focus on building consumer trust if plans to use its new health products for a broader healthcare play. On average, more than a third of consumers are ‘not at all comfortable sharing information as simple as personal fitness details and prescription records with Amazon in exchange for its services, per a May 2018 Alpha survey.”
Look at how far Amazon has to go in getting shoppers’personal information.
“Recently, two AI drug design companies, Insilico Medicine and A2A Pharmaceuticals joined forces to bring to market a possible treatment for Duchenne muscular dystrophy (DMD) and other rare orphan diseases. Using AI to more rapidly discover optimal pre-clinical candidates may revolutionize the drug development process in the life sciences.”
“What AI can bring to the table is the ability to rapidly and accurately sort through massive amounts of data. This may very well revolutionize how competitive intelligence, drug discovery and stakeholder engagement take place as we know it. Among many functions that medical affairs is tasked with, an important one is stakeholder engagement with External Experts (EE) (formerly known as KOLs or Key Opinion Leaders). For Medical Science Liaisons (MSLs), who are the primary function engaging external stakeholders, there will likely be several changes.”